Referências

1. (2021)
2. Kanesvaran R., Mohile S., Soto-Perez-de-Celis E, Singh H. The globalization of geriatric oncology: From data to practice, Am Soc Clin Oncol Educ Book, 40, pp. e107-e115, (2020)
3. White M.C., Holman D.M., Goodman R.A., Et al., Cancer risk among older adults: Time for cancer prevention to go silver, Gerontologist, 59, (2019)
4. Zhang X., Meng X., Chen Y., Leng S.X., Zhang H., The biology of aging and cancer: Frailty, inflammation, and immunity, Cancer J, 23, 4, pp. 201-205, (2017)
5. Soto-Perez-de-celis E., Li D., Yuan Y., Lau Y.M., Hurria A., Functional versus chronological age: Geriatric assessments to guide decision making in older patients with cancer, Lancet Oncol, 19, 6, (2018)
6. Wildiers H., Heeren P., Karnakis T., Hurria A., Et al., International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patient with Cancer, J Clin Oncol, 32, (2014)
7. Puts M.T., Santos B., Hardt J., Monette J., Atenafu E.G., Girre V., Et al., An update on a systematic review of the use of geriatric assessment for older adults in oncol­ogy, Ann Oncol, 25, 2, pp. 307-315, (2014)
8. Decoster L., Van Puyvelde K., Mohile S., Wedding U., Basso U., Colloca G., Rostoft S., Overcash J., Wildiers H., Steer C., Kimmick G., Kanesvaran R., Luciani A., Terret C., Hurria A., Kenis C., Audisio R., Extermann M., Screening tools for multidimensional health prob­lems warranting a geriatric assessment in older cancer patients: An update on SIOG recommendations†, Ann Oncol, 26, 2, pp. 288-300, (2015)
9. Biganzoli L., Wildiers H., Oakman C., Et al., Management of elderly patients with breast cancer: Updated recom­mendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA), Lancet J Oncol, 13, (2012)
10. McGale P., Taylor C., Correa C., Cutter D., Duane F., Ewertz M., Et al., Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 ran­domised trials, Lancet, 383, 9935, pp. 2127-2135, (2014)
11. Hughes K.S., Schnaper L.A., Bellon J.R., Et al., Lumpectomy plus tamoxifen with or without irradia­tion in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343, J Clin Oncol, 31, 19, pp. 2382-2387, (2013)
12. Murray Brunt A., Haviland J.S., Wheatley D.A., Sydenham M.A., Alhasso A., Bloomfield D.J., Et al., Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial, Lancet, 395, 10237, pp. 1613-1626, (2020)
13. Bartelink H., Horiot J.C., Poortmans P.M., Et al., Impact of a higher radiation dose on local control and sur­vival in breast-conserving therapy of early breast can­cer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 25, 22, pp. 3259-3265, (2007)
14. Collette S., Collette L., Budiharto T., Et al., Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: A study based on the EORTC trial 22881-10882 ‘boost versus no boost’, Eur J Cancer, 44, 17, pp. 2587-2599, (2008)
15. Vrieling C., Collette L., Fourquet A., Et al., The influ­ence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ’boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups, Radiother Oncol, 55, 3, pp. 219-232, (2000)
16. Vaidya J.S., Wenz F., Bulsara M., Tobias J.S., Joseph D.J., Keshtgar M., Flyger H.L., Massarut S., Alvarado M., Saunders C., Eiermann W., Metaxas M., Sperk E., Sutterlin M., Brown D., Esserman L., Roncadin M., Thompson A., Dewar J.A., Holtveg H.M.R., Pigorsch S., Falzon M., Harris E., Matthews A., Brew-Graves C., Potyka I., Corica T., Williams N.R., Baum M., Risk-adapted targeted intraoperative radiotherapy ver­sus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 9917, pp. 603-613, (2014)
17. Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., Leonardi M.C., Lazzari R., Cattani F., Gentilini O., Intra M., Caldarella P., Ballardini B., Intraoperative radiotherapy versus exter­nal radiotherapy for early breast cancer (ELIOT): A randomised controlled equivalence trial, Lancet Oncol, 14, 13, pp. 1269-1277, (2013)
18. Whelan T.J., Julian J.A., Berrang T.S., Kim D.H., Germain I., Nichol A.M., Et al., External beam accelerated par­tial breast irradiation versus whole breast irradiation after breast conserving surgery in women with duc­tal carcinoma in situ and node-negative breast can­cer (RAPID): A randomised controlled trial, Lancet, 394, 10215, pp. 2165-2172, (2019)
19. Vicini F.A., Cecchini R.S., White J.R., Arthur D.W., Julian T.B., Rabinovitch R.A., Et al., Long-term primary results of accelerated partial breast irradiation after breast­conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial, Lancet, 394, 10215, pp. 2155-2164, (2019)
20. Polgar C., Ott O.J., Hildebrandt G., Kauer-Dorner D., Knauerhase H., Major T., Et al., Late side-effects and cosmetic results of accelerated partial breast irra­diation with interstitial brachytherapy versus whole­breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial, Lancet Oncol, 18, 2, pp. 259-268, (2017)
21. Meattini I., Marrazzo L., Saieva C., Desideri I., Scotti V., Simontacchi G., Bonomo P., Greto D., Mangoni M., Scoccianti S., Lucidi S., Paoletti L., Fambrini M., Bernini M., Sanchez L., Orzalesi L., Nori J., Bianchi S., Pallotta S., Livi L., Accelerated partial-breast irradia­tion compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-Florence trial, J Clin Oncol, 24, (2020)
22. Meattini I., Saieva C., Marrazzo L., Et al., Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irra­diation for patients aged 70 years or older: Subgroup analysis from a randomized phase 3 trial, Breast Cancer Res Treat, 153, 3, pp. 539-547, (2015)
23. Bloomfield D.J., Development of postoperative radiotherapy for breast cancer: UK Consensus Statements—a Model of Patient, Clinical and Commissioner Engagement?, Clin Oncol (R Coll Radiol), 29, 10, pp. 639-641, (2017)
24. Polgar C., Van Limbergen E., Potter R., Et al., Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommen­dations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009), Radiother Oncol, 94, 3, pp. 264-273, (2010)
25. Icro M.C., Liesbeth B., Orit B., Nader K.-P.G., Angel M., Vrou M.B., Offersen Marianne C., Claus A., Murray B.A., Samantha B., Pierfrancesco D., Mechthild F., Mairead K., Tanja M., Livia M., Ivica M., Astrid R., Elzbieta S., Hilary S., Philip S., Poortmans Charlotte E., European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radio­therapy in early breast cancer, The Lancet Oncology, 23, 1, (2022)
26. Correa C., Harris E.E., Leonardi M.C., Et al., Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus state­ment, Pract Radiat Oncol, 7, 2, pp. 73-79, (2017)
27. Wilkinson J.B., Chen P.Y., Wallace M.F., Shah C.S., Benitez P.R., Martinez A.A., Vicini F.A., Six-year results from a phase I/II trial for hypofractionated accelerated partial breast irradiation using a 2-day dose schedule, Am J Clin Oncol, 41, 10, pp. 986-991, (2018)
28. Latorre J.A., Galdos P., Buznego L.A., Et al., Accelerated partial breast irradiation in a single 18 Gy frac­tion with high-dose-rate brachytherapy: Preliminary results, J Contemp Brachytherapy, 10, 1, pp. 58-63, (2018)
29. Jethwa K.R., Park S.S., Gonuguntla K., Et al., Three-fraction intracavitary accelerated partial breast brachytherapy: Early provider and patient-reported outcomes of a novel regimen, Int J Radiat Oncol Biol Phys, 104, 1, pp. 75-82, (2019)
30. Kinj R., Chand M.E., Gal J., Et al., Five-year oncologi­cal outcome after a single fraction of accelerated partial breast irradiation in the elderly, Radiat Oncol, 14, 1, (2019)
31. Hannoun-Levi J.M., Lam Cham Kee D., Gal J., Et al., Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation (SiFEBI) phase I/II trial, Brachytherapy, 19, 1, pp. 90-96, (2020)
32. Brain E., Caillet P., De Glas N., Biganzoli L., Cheng K., Lago L.D., Et al., HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology, J Geriatr Oncol, 10, 6, pp. 1003-1013, (2019)
33. Howie L.J., Singh H., Bloomquist E., Wedam S., Amiri-Kordestani L., Tang S., Sridhara R., Sanchez J., Prowell T.M., Kluetz P.G., King-Kallimanis B.L., Gao J.J., Ibrahim A., Goldberg K.B., Theoret M., Pazdur R., Beaver J.A., Outcomes of older women with hor­mone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: An FDA pooled analysis, J Clin Oncol, 37, 36, pp. 3475-3483, (2019)
34. Hurria A., Togawa K., Mohile S.G., Owusu C., Klepin H.D., Gross C.P., Et al., Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study, J Clin Oncol, 29, 25, pp. 3457-3465, (2011)
35. Extermann M., Boler I., Reich R.R., Lyman G.H., Brown R.H., Defelice J., Et al., Predicting the risk of chemo­therapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score, Cancer, 118, 13, pp. 3377-3386, (2012)
36. Magnuson A., Sedrak M.S., Gross C.P., Tew W.P., Klepin H.D., Wildes T.M., Muss H.B., Dotan E., Freedman R.A., O'Connor T., Dale W., Cohen H.J., Katheria V., Arsenyan A., Levi A., Kim H., Mohile S., Hurria A., Sun C.L., Development and validation of a risk tool for pre­dicting severe toxicity in older adults receiving che­motherapy for early-stage breast cancer, J Clin Oncol, 39, 6, pp. 608-618, (2021)
37. Kalsi T., Babic-Illman G., Fields P., Hughes S., Maisey N., Ross P., Wang Y., Harari D., The impact of low-grade toxicity in older people with cancer undergoing chemotherapy, Br J Cancer, 111, 12, pp. 2224-2228, (2014)
38. Meattini I., Poortmans P.M.P., Marrazzo L., Desideri I., Brain E., Hamaker M., Lambertini M., Miccinesi G., Russell N., Saieva C., Strnad V., Visani L., Kaidar P., Livi O.L., Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 -EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome mea­sures, J Geriatr Oncol, 12, 2, pp. 182-189, (2021)